Clinical Trials - November 13, 2025
Lytix Biopharma announces interim data on neoadjuvant treatment
Lytix Biopharma has announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma.
Clinical Trials - November 11, 2025
Arctic Therapeutics receives EMA approval for Phase IIa study in Alzheimer’s
The company has initiated a Phase IIa clinical trial to evaluate the safety and biomarker-based efficacy of AT-001 in individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Clinical Trials - November 10, 2025
Lytix Biopharma announces new immune response data
The company has presented immune response data on ruxotemitide (formerly LTX-315/VP-315) at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.
Clinical Trials - November 4, 2025
ScandiBio initiates Phase 3 trial: Mini-interview with Mathias Uhlén
The multicentre, phase 3 human clinical trial will evaluate the efficacy and safety of the company's pharmaceutical, Combined Metabolic Activator, in patients with Alzheimer's disease.
Clinical Trials - October 22, 2025
ACORAI presents positive results
The company has announced results from the 1,600-patient CAPTURE-HF study (Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-Invasive Multi-sensor Device).
Biotech Business - October 22, 2025
Abera reports long-term data for its nasal influenza vaccine
The results show that the vaccine generates strong and long-lasting immune responses both at the mucosal surfaces and systemically.
